Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cell cycle and drug sensitivity.

Aslamuzzaman Kazi1, Q Ping Dou

  • 1Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, USA.

Methods in Molecular Medicine
|May 25, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FGTI-2734 prevents ERK-mediated resistance and enhances MRTX1133 efficacy in KRAS G12D pancreatic cancer.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Geranylgeranyl transferase-1 inhibitor GGTI-2417 enhances the anti-tumour efficacy of histone deacetylase inhibitors in different T-cell lymphoma lines.

British journal of haematology·2025
Same author

Ubiquitin-Specific Protease Inhibitors for Cancer Therapy: Recent Advances and Future Prospects.

Biomolecules·2025
Same author

FGTI-2734 Inhibits ERK Reactivation to Overcome Sotorasib Resistance in KRAS G12C Lung Cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2024
Same author

Correction: CD28 Costimulatory Domain-Targeted Mutations Enhance Chimeric Antigen Receptor T-cell Function.

Cancer immunology research·2024
Same author

Metastatic Lymph Node 64 (MLN64) Expression in Gastric Cancer: The Clinical and Molecular Implications in Drug Resistance.

Cancer genomics & proteomics·2023

Chemotherapy effectiveness varies with cancer cell cycle phases. This study synchronizes cells to investigate how anticancer drugs induce tumor cell death, providing insights into chemosensitivity mechanisms.

Area of Science:

  • Oncology
  • Cell Biology
  • Pharmacology

Background:

  • Chemotherapeutic agents induce tumor cell death, often in a cell cycle-dependent manner.
  • Key regulatory proteins influencing tumor chemosensitivity and apoptosis exhibit periodic expression during cell cycle progression.
  • The precise mechanisms of anticancer drug action and cancer cell sensitivity across different cell cycle phases remain largely unelucidated.

Purpose of the Study:

  • To investigate the cell cycle-dependent cytotoxic effects of chemotherapeutic agents on human tumor cells.
  • To establish reliable methods for synchronizing tumor cells in specific cell cycle phases.
  • To quantify the impact of anticancer drugs on cell death induction at distinct cell cycle stages.

Main Methods:

  • Cell cycle synchronization using serum deprivation and pharmacological agents.

Related Experiment Videos

  • Induction of cell death in synchronized human tumor cells with anticancer drugs.
  • Assessment of cell cycle-associated cytotoxicity via flow cytometry, Western blot, and DNA fragmentation assays.

    • Main Results:

    • Established protocols for synchronizing human tumor cells in specific cell cycle phases.
    • Demonstrated the capability to measure cell cycle-dependent cytotoxic effects of chemotherapeutic agents.
    • Provided a framework for analyzing the impact of drug treatment across different cell cycle stages.

    Conclusions:

    • Anticancer drug efficacy is significantly influenced by the cell cycle phase of tumor cells.
    • Understanding cell cycle-dependent chemosensitivity is crucial for optimizing cancer treatment strategies.
    • The described methods facilitate detailed investigation into the mechanisms of chemotherapeutic action and resistance.